The current financial score of Pacific Biosciences of California Inc is 5.35. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 39.01M, representing a year-over-year decrease of 1.91%, while its net profit experienced a year-over-year decrease of 6.70%.
The current valuation score of Pacific Biosciences of California Inc is 8.91. Its current P/E ratio is -3.15, which is -87.28% below the recent high of -0.40 and -226.45% above the recent low of -10.27.
The current earnings forecast score of Pacific Biosciences of California Inc is 7.25. The average price target is 2.16, with a high of 3.00 and a low of 1.25.
The current price momentum score of Pacific Biosciences of California Inc is 5.07. Currently, the stock price is trading between the resistance level at 1.57 and the support level at 1.08, making it suitable for range-bound swing trading.
The current institutional shareholding score of Pacific Biosciences of California Inc is 5.00. The latest institutional shareholding proportion is 62.12%, representing a quarter-over-quarter increase of 10.93%. The largest institutional shareholder is Catherine Wood, holding a total of 29.78M shares, representing 0.32% of shares outstanding, with 29.76% decrease in holdings.
The current risk assessment score of Pacific Biosciences of California Inc is 4.14. The company's beta value is 2.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.